Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TSPO | P30536 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10128868 | 0.83 | HTR2C (0.42) | HTR2CMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL10128829 | 0.81 | POLB (0.44) | TP53POLBMAPTTSPOKDM4E | |
| SCHEMBL10128834 | 0.78 | PDE4B (0.35) | TP53POLBMAPTTSPOKDM4E | |
| SCHEMBL10128833 | 0.78 | TSPO (0.34) | POLBMAPTTSPOMEN1ALDH1A1 | |
| SCHEMBL515190 | 0.76 | POLB (0.50) | POLBMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL19344751 | 0.76 | POLB (0.42) | TP53POLBMAPTTSPO | |
| SCHEMBL10128852 | 0.75 | PDE2A (0.43) | POLBTSPO | |
| SCHEMBL10128481 | 0.75 | POLB (0.44) | KAT2BTP53POLBMAPTALDH1A1 | |
| SCHEMBL10128842 | 0.74 | POLB (0.48) | POLBMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL10128851 | 0.73 | POLB (0.44) | POLBMAPTKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034486-B2 | Triazole derivative, heterocyclic compound, light-emitting element, light-emitting device, electronic device and lighting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD (JP) | 2015-05-19 | — | — | US | disclosed |
| US-9034486-B2 | Triazole derivative, heterocyclic compound, light-emitting element, light-emitting device, electronic device and lighting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD (JP) | 2015-05-19 | — | — | US | disclosed |
| WO-2012017842-A1 | TRIAZOLE DERIVATIVE, HETEROCYCLIC COMPOUND, LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, ELECTRONIC DEVICE AND LIGHTING DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2012-02-09 | — | — | WO | disclosed |
| US-20120025697-A1 | Triazole Derivative, Heterocyclic Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device and Lighting Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2012-02-02 | — | — | US | disclosed |
| US-20120025697-A1 | Triazole Derivative, Heterocyclic Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device and Lighting Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120025697-A1 | Triazole Derivative, Heterocyclic Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device and Lighting Device | HTR3D, KCNQ4, KCNQ3 | KAT2B 2749/4885TP53 4442/4885HTR2C 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.